Oral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.
Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Colistimethate. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Colistimethate. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Colistimethate. |
| Cisatracurium | The therapeutic efficacy of Cisatracurium can be increased when used in combination with Colistimethate. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Colistimethate. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Colistimethate. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Colistimethate. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Colistimethate. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Colistimethate. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Colistimethate. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Colistimethate. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Colistimethate. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Colistimethate. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Colistimethate. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Colistimethate. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Colistimethate. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Colistimethate. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Colistimethate. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Colistimethate. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Colistimethate. |
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Foscarnet. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Colistimethate. |
| Tenofovir disoproxil | Colistimethate may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | Colistimethate may increase the nephrotoxic activities of Tenofovir alafenamide. |
| Tenofovir | Colistimethate may increase the nephrotoxic activities of Tenofovir. |
| Amphotericin B | Amphotericin B may increase the nephrotoxic activities of Colistimethate. |
| Polymyxin B | Polymyxin B may increase the nephrotoxic and neuromuscular blocking activities of Colistimethate. |
| Cyclosporine | The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Colistimethate. |
| Icosapent | The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Colistimethate. |
| Cefotiam | The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Colistimethate. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Colistimethate. |
| Cefmenoxime | The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Colistimethate. |
| Cefmetazole | The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Colistimethate. |
| Indomethacin | The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Colistimethate. |
| Triamterene | The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Colistimethate. |
| Cefpiramide | The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Colistimethate. |
| Loracarbef | The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Colistimethate. |
| Cefalotin | The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Colistimethate. |
| Nabumetone | The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Colistimethate. |
| Ketorolac | The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Colistimethate. |
| Tenoxicam | The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Colistimethate. |
| Celecoxib | The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Colistimethate. |
| Cefotaxime | The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Colistimethate. |
| Tolmetin | The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Colistimethate. |
| Rofecoxib | The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Colistimethate. |
| Fenoprofen | The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Colistimethate. |
| Valdecoxib | The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Colistimethate. |
| Diclofenac | The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Colistimethate. |
| Sulindac | The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Colistimethate. |
| Bacitracin | The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Colistimethate. |
| Cephaloglycin | The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Colistimethate. |
| Adefovir dipivoxil | The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Colistimethate. |
| Pentamidine | The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Colistimethate. |
| Mefenamic acid | The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Colistimethate. |
| Naproxen | The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Colistimethate. |
| Sulfasalazine | The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Colistimethate. |
| Phenylbutazone | The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Colistimethate. |
| Meloxicam | The risk or severity of nephrotoxicity can be increased when Meloxicam is combined with Colistimethate. |
| Carprofen | The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Colistimethate. |
| Tacrolimus | The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Colistimethate. |
| Etacrynic acid | The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Colistimethate. |
| Ceforanide | The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Colistimethate. |
| Salicylic acid | The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Colistimethate. |
| Acetylsalicylic acid | The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Colistimethate. |
| Hydrochlorothiazide | The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Colistimethate. |
| Balsalazide | The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Colistimethate. |
| Cefditoren | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Colistimethate. |
| Atazanavir | The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Colistimethate. |
| Cefuroxime | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefuroxime. |
| Cefapirin | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefapirin. |
| Cefprozil | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefprozil. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Olsalazine. |
| Lumiracoxib | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Lumiracoxib. |
| Cefamandole | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefamandole. |
| Cefazolin | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefazolin. |
| Cefonicid | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefonicid. |
| Cefoperazone | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefoperazone. |
| Cefoxitin | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefoxitin. |
| Ceftizoxime | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Ceftizoxime. |
| Magnesium salicylate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Magnesium salicylate. |
| Salsalate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Salsalate. |
| Choline magnesium trisalicylate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Choline magnesium trisalicylate. |
| Cefepime | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefepime. |
| Cefacetrile | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefacetrile. |
| Cefpodoxime | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefpodoxime. |
| Antrafenine | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Antrafenine. |
| Aminophenazone | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Aminophenazone. |
| Antipyrine | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Antipyrine. |
| Tiaprofenic acid | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Tiaprofenic acid. |
| Lopinavir | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Lopinavir. |
| Etoricoxib | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Etoricoxib. |
| Hydrolyzed Cephalothin | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Hydrolyzed Cephalothin. |
| Cephalothin Group | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cephalothin Group. |
| Oxyphenbutazone | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Oxyphenbutazone. |
| Latamoxef | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Latamoxef. |
| Nimesulide | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Nimesulide. |
| Benoxaprofen | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Benoxaprofen. |
| Metamizole | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Metamizole. |
| Zomepirac | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Zomepirac. |
| Ceftobiprole | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Ceftobiprole. |